Emergent BioSolutions, Inc., acquires license for pandemic influenza vaccine candidate
The Maryland-based company said that it has acquired the rights to manufacture and sell VaxInnate's recombinant pandemic influenza vaccine candidate in the United States. The vaccine candidate is able to be produced quickly and in large quantities, making it suitable for use in an emergency.
Under the agreement, VaxInnate will continue to develop the vaccine candidate as part of its contract with the U.S. Biomedical Advanced Research and Development Authority, and Emergent BioSolutions, Inc., will develop the flexible manufacturing technology necessary to produce it.
The deal allows Emergent BioSolutions, Inc., to fulfill its own pandemic vaccine contract with BARDA, which established the company as a Center for Innovation in Advanced Development and Manufacturing in June.
"This transaction, which secures manufacturing rights to a next generation pandemic influenza vaccine candidate, is a step towards satisfying Emergent's commitment to BARDA as a Center for Innovation in Advanced Development and Manufacturing," Daniel J. Abdun-Nabi, the president and chief executive officer of Emergent BioSolutions, Inc., said. "Our public-private partnership with BARDA, which taps into our core manufacturing capabilities and infrastructure, provides a real opportunity to make significant progress to address the nation's medical countermeasure manufacturing requirements. We look forward to continuing to work with BARDA to achieve that important goal."